Advertisement

Clinical Assessment, Monitoring and Therapeutic Strategies for Septic Patients

  • B. Vallet
Conference paper

Abstract

Sepsis is considered as the leading cause of death in non-coronary intensive care units (ICUs). Its early recognition and management should contribute to optimum therapeutic approach [1]. The clinical features of sepsis comprise those resulting from the primary insult, those pertaining to systemic inflammatory activation, and those resulting from end-organ dysfunction. There are two strands to current management: 1) antibiotic therapy and any means that can eradicate the infecting organism and thus halt its stimulation of the inflammatory response; 2) close monitoring and support of the patient in order to minimize the adverse effects of the inflammatory response on perfusion, oxygenation and organ function. However, and unfortunately, there is no regularly used current treatment aimed specifically at neutralising or inhibiting the endogenous inflammatory mediators.

Keywords

Septic Shock Mean Arterial Pressure Septic Patient Multiple Organ Dysfunction Syndrome Simplify Acute Physiologic Score 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Brun-Buisson C, Doyon F, Carlet J et al (1995) Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. JAMA 274: 968–974PubMedCrossRefGoogle Scholar
  2. 2.
    Lamy M, Deby-Dupont G (1995) Is sepsis a mediator-inhibitor mismatch? Intensive Care Med 21: S250–S257PubMedCrossRefGoogle Scholar
  3. 3.
    Balk RA (1994) Septic shock: pathophysiology. Curr Opin Anesthaesiol 7: 136–140CrossRefGoogle Scholar
  4. 4.
    Tracey KJ, Cerami A (1993) Tumor necrosis factor: an updated review of its biology. Crit Care Med 21: S415–S422PubMedCrossRefGoogle Scholar
  5. 5.
    American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference (1992) Definitions for sepsis and organ falure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20: 864–874CrossRefGoogle Scholar
  6. 6.
    Parrillo JE (1993) Pathogenetic mechanisms of septic shock. N Engl J Med 328: 1471–1477PubMedCrossRefGoogle Scholar
  7. 7.
    Bernardin G, Pradier C, Tiger F et al (1996) Blood pressure and arterial lactate level are early indicators of short term survival in human septic shock. Intensive Care Med 22: 17–25PubMedCrossRefGoogle Scholar
  8. 8.
    Metrangolo L, Fiorillo M, Friedman G et al (1995) Early hemodynamic course of septic shock. Crit Care Med 23: 1971–1975PubMedCrossRefGoogle Scholar
  9. 9.
    Vallet B, Chopin C, Curtis SE et al (1993) Prognostic value of the dobutamine test in patients with sepsis syndrome and normal lactate values: a prospective, multicenter study. Crit Care Med 21: 1868–1875PubMedCrossRefGoogle Scholar
  10. 10.
    Rhodes A, Malagnon I, Lamb FJ et al (1996) Failure to increase oxygen consumption is a predictor of mortality in septic patients. Intensive Care Med 22: S274CrossRefGoogle Scholar
  11. 11.
    Hayes MA, Timmins AC, Yau EHS et al (1997) Oxygen transport patterns in patients with sepsis syndrome or septic shock: influence of treatment and relationship to outcome. Crit Care Med 25: 926–936PubMedCrossRefGoogle Scholar
  12. 12.
    Hayes MA, Timmins AC, Yau EHS et al (1994) Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 330: 1717–1722PubMedCrossRefGoogle Scholar
  13. 13.
    Gutierrez G, Clark C, Brown SD et al (1994) Effect of dobutamine on oxygen consumption and gastric mucosal pH in septic patients. Am J Respir Crit Care Med 150: 324–329PubMedGoogle Scholar
  14. 14.
    Gutierrez G, Palizas F, Doglio G et al (1992) Gastric intramucosal pH as a therapeutic index of tissue oxygenation in critically ill patients. Lancet 339: 195–199PubMedCrossRefGoogle Scholar
  15. 15.
    Vallet B, Lund N, Curtis SE et al (1994) Gut and muscle tissue PO2 in endotoxemic dogs during shock and resuscitation. J Appl Physiol 76: 793–800PubMedGoogle Scholar
  16. 16.
    Hasibeder W, Germann R, Wolf HJ et al (1996) The effects of short-term endotoxemia and dopamine on mucosal oxygenation in the porcine jejunum. Am J Physiol 270: G667–G675PubMedGoogle Scholar
  17. 17.
    Fink MP (1991) Gastrointestinal mucosal injury in experimental models of shock, trauma and sepsis. Crit Care Med 19: 627–641PubMedCrossRefGoogle Scholar
  18. 18.
    Vincent JL, Preiser JC (1993) Inotropic agents. New Horizons 1: 137–144PubMedGoogle Scholar
  19. 19.
    Raphaël JC, Antony I, Bellissant E et al (1996) Catecholamine use during septic shock. Rean Urg 5: 441–450CrossRefGoogle Scholar
  20. 20.
    Desjars P, Pinaud M, Potel G et al (1987) A reappraisal of norepinephrine in human septic shock. Crit Care Med 15: 134–137PubMedCrossRefGoogle Scholar
  21. 21.
    Redl-Wenzl EM, Armbruster C, Edelmann G et al (1993) The effects of norepinephrine on hemodynamics and renal function in severe septic shock states. Intensive Care Med 19: 151–154PubMedCrossRefGoogle Scholar
  22. 22.
    Meier-Hellmann A, Reinhart K (1997) Cardiovascular support by hemodynamic subset: sepsis. In: Pinsky MR (ed) Applied cardiovascular physiology. Springer, Berlin, pp 231–245Google Scholar
  23. 23.
    Cobb JP, Danner RL (1996) Nitric oxide and septic shock. JAMA 275: 1192–1196PubMedCrossRefGoogle Scholar
  24. 24.
    Petros A, Lamb G, Leone A et al (1994) Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res 28: 34–39PubMedCrossRefGoogle Scholar
  25. 25.
    Vincent JL, Roman A, Kahn RJ (1990) Dobutamine administration in septic shock: addition to a standard protocol. Crit Care Med 18: 689–693PubMedCrossRefGoogle Scholar
  26. 26.
    Nevière R, Chagnon JL, Vallet B et al (1997) Dobutamine improves gastro-intestinal mucosal blood flow in a porcine model of endotoxic shock. Crit Care Med (in press)Google Scholar
  27. 27.
    Smithies M, Yee TH, Jackson L et al (1994) Protecting the gut and the liver in the critically ill: effects of dopexamine. Crit Care Med 22: 789–795PubMedCrossRefGoogle Scholar
  28. 28.
    Nevière R, Mathieu D, Chagnon JL et al (1996) The contrasting effects of dobutamine and dopamine on gastric mucosal blood perfusion in septic patients. Am J Respir Crit Care Med 154: 1684–1688PubMedGoogle Scholar
  29. 29.
    Levy B, Bollaert PE, Charpentier C et al (1997) Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock: a prospective, randomized study. Intensive Care Med 23: 282–287PubMedCrossRefGoogle Scholar
  30. 30.
    Radermacher P, Buhl R, Santak B et al (1995) The effects of prostacyclin on gastric intramucosal pH in patients with septic shock. Intensive Care Med 21: 414–421PubMedCrossRefGoogle Scholar
  31. 31.
    Liu M, Slutsky AS (1997) Anti-inflammatory therapies: application of molecular biology techniques in intensive care medicine. Intensive Care Med 23: 718–731PubMedCrossRefGoogle Scholar
  32. 32.
    Ziegler EJ, Fisher CJ, Sprung CL et al (1991) Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double-blind, placebo-controlled trial. N Engl J Med 324: 429–436PubMedCrossRefGoogle Scholar
  33. 33.
    Warren HS, Danner RL, Mundord RS (1992) Sounding board: antiendotoxin antibodies. N Engl J Med 326: 1153–1157PubMedCrossRefGoogle Scholar
  34. 34.
    Fisher CJ, Slotman GJ, Opal SM et al (1994) Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 22: 12–21PubMedGoogle Scholar
  35. 35.
    Slotman GJ, Quinn JV, Brathwaite CEM et al (1996) The systemic mediator-associated response test (SMART) predicts organ function in sepsis syndrome. Crit Care Med 24: A53Google Scholar

Copyright information

© Springer-Verlag Italia, Milano 1998

Authors and Affiliations

  • B. Vallet

There are no affiliations available

Personalised recommendations